Literature DB >> 10615003

FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery.

H P Wendel1, D W Jones, M J Gallimore.   

Abstract

A new chromogenic peptide substrate assay kit was used to measure factor XII (FXII) levels in plasma samples from 115 male patients with heart disease awaiting cardiac surgery, 40 age-matched normal healthy male blood donors and 20 patients before, during and after cardiopulmonary bypass surgery (CPB). Kallikrein-like and FXIIa-like activities were also determined in the CPB patient group. FXII levels were significantly lower (p = 0.0049) in the heart disease patients awaiting surgery when compared with values for the healthy donors and 13 patients (11.3%) had FXII levels below 50% compared with 1 normal donor (2.5%). During CPB significant decreases in FXII levels and significant increases in FXIIa-like and kallikrein-like activities were found indicating activation of the FXII-plasma kallikrein pathway during CPB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10615003     DOI: 10.1016/s0162-3109(99)00067-3

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  9 in total

Review 1.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

Review 2.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

Review 3.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

4.  Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.

Authors:  Ivan Ivanov; Ruhama Shakhawat; Mao-Fu Sun; S Kent Dickeson; Cristina Puy; Owen J T McCarty; Andras Gruber; Anton Matafonov; David Gailani
Journal:  Thromb Haemost       Date:  2017-01-26       Impact factor: 5.249

Review 5.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

Review 6.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Authors:  Benjamin Tillman; David Gailani
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

7.  Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation.

Authors:  Ivan Ivanov; Anton Matafonov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Blood       Date:  2017-01-09       Impact factor: 22.113

Review 8.  The Effects of the Contact Activation System on Hemorrhage.

Authors:  Fabrício Simão; Edward P Feener
Journal:  Front Med (Lausanne)       Date:  2017-07-31

Review 9.  The rebirth of the contact pathway: a new therapeutic target.

Authors:  Priyanka Srivastava; David Gailani
Journal:  Curr Opin Hematol       Date:  2020-09       Impact factor: 3.218

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.